Picture of Celltrion Healthcare Co logo

091990 — Celltrion Healthcare Co News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareAdventurousLarge Cap

Brief: Celltrion Healthcare Announces Acceptance And Priority Review By Health Canada Of New Drug Submission For Its Monoclonal Antibody Treatment For Covid-19, Regdanvimab (Ct-P59)

Aug 2 (Reuters) - Celltrion HealthCare Co Ltd  091990.KQ :
    * CELLTRION HEALTHCARE ANNOUNCES ACCEPTANCE AND PRIORITY
REVIEW BY
HEALTH CANADA OF NEW DRUG SUBMISSION FOR ITS MONOCLONAL ANTIBODY
TREATMENT FOR COVID-19, REGDANVIMAB (CT-P59)

Source text for Eikon:  ID:nCNWr3V1Va 
Further company coverage:  091990.KQ 

 ((reuters.briefs@thomsonreuters.com;))

Recent news on Celltrion Healthcare Co

See all news